Adaptimmune Therapeutics PLC (ADAPY): Shareholders' Equity
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$11.85M
As of 2024-12-31
-$70.96M
As of 2025-06-30
-61.4%
3-year compound annual growth
-37.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $11.85M | -70.0% | 2025-03-24, Balance as of period end |
| 2023-12-31 | $39.51M | -51.7% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $81.88M | -60.2% | 2025-03-24, Balance as of period end |
| 2021-12-31 | $205.96M | -39.6% | 2024-03-06, Balance as of period end |
| 2020-12-31 | $341.23M | +176.0% | 2023-03-06, Balance as of period end |
| 2019-12-31 | $123.64M | -49.9% | 2022-03-14, Balance as of period end |
| 2018-12-31 | $246.88M | +21.6% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $202.98M | +22.2% | 2018-03-15, Balance as of period end |
| 2016-12-31 | $166.14M | -29.3% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $234.99M | n/a | 2018-03-15, Balance as of period end |
| 2015-06-30 | $259.00M | n/m | 2018-03-15, Balance as of period end |
| 2014-06-30 | $2.96M | n/a | 2017-03-13, Balance as of period end |